HALO Halozyme Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
03:20
Aug 10
Aug 10
Royalty-based biotech companies offer high earnings visibility.
CMO/CDMO and SC formulation biotech companies like Halozyme and Alteogen offer high earnings visibility due to royalty-based models, making them attractive in a high-rate environment.
HIGH
11:22
Aug 07
Aug 07
HALO attractive after good earnings
Buy HALO following good Q2 earnings; speaker finds valuation still attractive after results, suggesting the stock has not fully priced in the positive earnings outcome.
MED
12:00
Jul 28
Jul 28
Collaborating with Halozyme to optimize the subcutaneous formulation of 9A9 using their enhanced delivery technology adds optionality and could improve patient experience for the drug.
HIGH
16:20
Jul 26
Jul 26
Author discloses Halozyme as one of their top 5 current holdings.
Author discloses Halozyme as one of their top 5 current holdings, indicating an active long position with personal conviction.
MED
22:36
Jul 07
Jul 07
Author states a long position in HALO with no explicit catalyst.
Author states a long position in HALO with no explicit catalyst; reply context references biotech sector strength relative to correcting AI/tech names, but no specific reasoning is provided by the author.
MED
13:41
Jun 04
Jun 04
Speaker flags HALO as more interesting in the context of NVO's oral GLP-1 launch.
Speaker flags HALO as more interesting in the context of NVO's oral GLP-1 launch, with no explicit reason or price target provided.
LOW
22:03
Jun 01
Jun 01
Buy HALO as a top pick within specialty pharma; author nominates it as the most attractive name.
Buy HALO as a top pick within specialty pharma; author nominates it as the most attractive name in the sector in response to a direct solicitation for ideas, though no specific catalyst or data point is provided.
MED
22:01
Jun 01
Jun 01
Notes HALO receives ~5% royalties from the subcutaneous formulation of Darzalex.
LOW
20:31
May 14
May 14
HALO ETF: heavy assets, low obsolescence.
The HALO ETF invests in companies with heavy physical assets and low obsolescence risk, making them immune to AI disruption. These are durable businesses that can withstand advances in large language models and agentic AI because their value is in hard assets, not software or services that could be displaced. The ETF provides a way to own the market while avoiding the most disruptive, AI-vulnerable names.
MED
14:27
May 12
May 12
Long $HALO (Halozyme) — speaker massively reinforced position.
Long $HALO (Halozyme) — speaker massively reinforced position; sees HALO and GMAB as two siphons capturing Darzalex revenues.
HIGH
17:51
Apr 04
Apr 04
Speaker positively characterizes the HALO trade as well considered and notes.
Speaker positively characterizes the HALO trade as well considered and notes asset-light/durability as alpha hunting grounds, but does not commit to a personal directional position.
LOW
About HALO Analyst Coverage
Buzzberg tracks HALO (Halozyme) across 5 sources. 7 bullish vs 0 bearish calls from 5 analysts. Sentiment: predominantly bullish (64%). 11 total trade ideas tracked. Past 7 days: 2 bullish. Latest voices: Lee Hyuk-jin, frenchv33921, Pablo.